Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas
Authors:
- Klaus KuchelmeisterKKKlaus Kuchelmeister
- Walter SchachenmayrWSWalter Schachenmayr
- Juergen SchlegelJSJuergen Schlegel
- 1 October 2004
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 101 (4) , 653-658
Abstract
Object. The mismatch repair (MMR) system has previously been implicated in acquired chemoresistance in malignant gliomas in humans. Its impact on the primary chemoresistance in glioblastoma multiforme (GBM) has not been determined in detail, however. Methods. The authors investigated the expression of both the MMR genes (hMSH2, hMLH1, hPMS1, hPMS2, and hMSH6) at the transcriptional level through reverse transcription—polymerase chain reaction and the hMSH2 protein through Western blot and immunohistochemical analysis of tumor tissue and primary cell cultures of 25 in vitro human de novo GBMs without prior experimental treatment. Results of these analyses were compared with data on in vitro chemoresistance to nine drugs that are in general use in glioma therapy. All MMR genes were expressed in the GBMs, with no significant difference among the individual tumors except in one respect; that is, GBMs showed either relatively high levels or barely detectable levels of hMSH2 messenger (m)RNA and protein expression. All multiresistant tumors demonstrated high hMSH2 expression, and all but two of the sensitive tumors exhibited low hMSH2 mRNA levels. Conclusions. Analysis of the data indicates that functional alterations of the MMR system are involved in the primary drug resistance in in vitro human malignant gliomas. Analysis of hMSH2 expression might therefore predict therapeutic responses in humans with GBMs.Keywords
This publication has 15 references indexed in Scilit:
- Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineageJournal of Cancer Research and Clinical Oncology, 2001
- Glioblastoma multiforme: The terminatorProceedings of the National Academy of Sciences, 2000
- Involvement of the DNA mismatch repair system in antineoplastic drug resistanceJournal of Cancer Research and Clinical Oncology, 1999
- Mismatch repair deficiency associated with overexpression of the MSH3 geneProceedings of the National Academy of Sciences, 1998
- DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSα/hMutSβ ratio and reduces the efficiency of base–base mismatch repairProceedings of the National Academy of Sciences, 1997
- Recognition and Repair of Compound DNA Lesions (Base Damage and Mismatch) by Human Mismatch Repair and Excision Repair SystemsMolecular and Cellular Biology, 1997
- Analysis of microsatellite repeats in pediatric brain tumorsCancer Genetics and Cytogenetics, 1995
- The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancerCell, 1993
- Clues to the Pathogenesis of Familial Colorectal CancerScience, 1993
- Response of cultured human brain tumors to nitrosoureas: Correlation with clinical dataCancer, 1981